Back

Synergistic efficacy of tigecycline combined with apramycin against tet(X)-harboring Acinetobacter spp.

Liu, J.; Zheng, S.-L.; Wu, J. J.; Zheng, M.; Cai, D.-T.; Zhang, Y.; Sun, J.; Liu, Y.-H.; Liao, X.-P.; Yu, Y.

2023-07-23 pharmacology and toxicology
10.1101/2023.07.20.549942 bioRxiv
Show abstract

The emergence of the wide variety of novel tigecycline resistance tet(X) variants including tet(X3), tet(X4), tet(X5) and tet(X6) has posed a significant challenge to the clinical treatment of multidrug-resistant bacterial infections and represents a serious threat to global public health. The purpose of this study was to evaluate the synergism of tigecycline combined with other antibiotics as a means of overcoming tet(X)-mediated resistance in Acinetobacter spp. We found that the combinations of tigecycline with apramycin or amikacin exhibited synergistic activity against tet(X)-harboring Acinetobacter spp. with FICI values of 0.088 and 0.625, respectively. The MICTGC decreased >5-fold decrease in the presence of subinhibitory levels of apramycin. This combination was shown to be a therapeutically effective synergism using both in vitro and in vivo (mouse thigh infection model) assays and delayed the increase of MIC values over time. This study highlights the synergism of tigecycline in combination with apramycin which offers a viable therapeutic alternative for infections caused by tet(X)-harboring Acinetobacter.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.